RPS6KB2

Across TCGA pan-cancer cohorts, RPS6KB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPS6KB2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPS6KB2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPS6KB2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and GBM are the cancer types where RPS6KB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.771	0.518	<.001	57	view →
PDAC	OS	Median	II,III,IV	0.560	0.287	.010	7	view →
GBM	DFS	Median	All	0.274	0.455	.017	4	view →
LUAD	OS	Quartile	III,IV	0.372	0.779	.015	4	view →
LSCC	OS	Quartile	All	0.895	0.685	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPS6KB2–HNSC (DFS)

Open the HNSC breakdown →